European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice
Summary The present guideline summarizes all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed‐type hypersensitivity skin and mucosal conditions. Sections with brief descriptio...
Saved in:
Published in: | Contact dermatitis Vol. 73; no. 4; pp. 195 - 221 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Oxford, UK
Blackwell Publishing Ltd
01-10-2015
Wiley Subscription Services, Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Summary
The present guideline summarizes all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed‐type hypersensitivity skin and mucosal conditions. Sections with brief descriptions and discussions of different pertinent topics are followed by a highlighted short practical recommendation. Topics comprise, after an introduction with important definitions, materials, technique, modifications of epicutaneous testing, individual factors influencing the patch test outcome or necessitating special considerations, children, patients with occupational contact dermatitis and drug eruptions as special groups, patch testing of materials brought in by the patient, adverse effects of patch testing, and the final evaluation and patient counselling based on this judgement. Finally, short reference is made to aspects of (continuing) medical education and to electronic collection of data for epidemiological surveillance. |
---|---|
Bibliography: | Uriach Pharma ArticleID:COD12432 GlaxoSmithKline Appendix S1. Professional training in cutaneous allergy. Unilever Intendis - Bayer istex:81A23000794346CF037C1F084481DC9181E4B61B Novartis l'ARCAA ark:/67375/WNG-BBKPTG3R-M ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Instructional Material/Guideline-2 ObjectType-Feature-3 content type line 23 |
ISSN: | 0105-1873 1600-0536 1600-0536 |
DOI: | 10.1111/cod.12432 |